Trial Profile

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IDE 034 (Primary)
Indications Colorectal cancer; Gynaecological cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors IDEAYA Biosciences

04 Aug 2026 According to Biocytogen Pharmaceuticals media release, company is planning to provide preliminary safety and efficacy data clinical data from its ongoing Phase 1 dose escalation trial by the end of 2026 or early 2027'
05 May 2026 According to Biocytogen Pharmaceuticals media release, company is targeting to provide a clinical data update from the trial by the end of 2026.
28 Feb 2026 Status changed from planning to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com